Schellack Carola, Prinz Karin, Egyed Alena, Fritz Jörg H, Wittmann Barbara, Ginzler Michael, Swatosch Gabriele, Zauner Wolfgang, Kast Constantia, Akira Shizuo, von Gabain Alexander, Buschle Michael, Lingnau Karen
Intercell AG, Campus Vienna Biocenter 6, 1030 Wien, Austria.
Vaccine. 2006 Jun 29;24(26):5461-72. doi: 10.1016/j.vaccine.2006.03.071. Epub 2006 Apr 7.
IC31, the combination of a novel immunostimulatory oligodeoxynucleotide containing deoxy-Inosine/deoxy-Cytosine (ODN1a) and the antimicrobial peptide KLKL(5)KLK, represents a promising novel adjuvant signaling via the TLR9/MyD88-dependent pathway of the innate immune system. In mice, IC31 induces potent peptide-specific type 1 cellular immune responses, as well as mainly type 1 dominated protein-specific cellular and humoral immune responses. In addition, cytotoxic T lymphocytes were induced, able to kill efficiently target cells in vivo. Activation of murine dendritic cells by IC31 induced efficiently proliferation of naïve CD4(+) TCR transgenic T cells (DO.11.10) as well as their differentiation into IFN-gamma- and IL-4-producing T cells in vitro.
